| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of TScan Therapeutics (NASDAQ:TCRX) through any online brokerage.
Other companies in TScan Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
TScan Therapeutics has a consensus price target of $6.67.
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $0.272 last updated October 7, 2026 at 7:54 AM EDT.
There are no upcoming dividends for TScan Therapeutics.
TScan Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for TScan Therapeutics.
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
